
PR/Comms, @noom. Formerly: @pagayaltd, @nbcnews, @qz, @FT. Sunglasses junkie, candy enthusiast, Rock Chalk. Views are my own. [email protected]
NYC
Joined June 2009
- Tweets6.5K
- Following2.8K
- Followers2.1K
- Likes6.7K
Pinned Tweet
Replying to @EmilyPasser
I'm thrilled to share that I've started as head of communications for @noom, a company sitting at the intersection of health, technology and human behavior and with the power to deeply influence the broader health landscape. 3/4
1
2
226
This week on The MM+M Podcast, @Noom CEO Geoff Cook talks “Weight Regain Doesn’t Care,” the impact of the broader Losing for Keeps effort, the role of celebs in GLP-1 marketing and what other examples of GLP-1 advertising have impressed him.
mmm-online.com/podcasts/noom…
Emily Passer retweeted
$HIMS
🚨 BREAKING: FDA PEPTIDES PANEL VOTES "YES" ON 6 OUT OF 7 PEPTIDES
1. BPC-157
2. KPV
3. TB-500
4. MOTS-C
5. EPITALON
6. SEMAX
THE ONE "NO" VOTE: EMIDELTIDE
Excited to introduce Lose for Keeps — Noom's new campaign featuring Rebel Wilson, now launched across TV, streaming, social, and digital.
Medication can create an opening for change. Habits help make it last.
Watch the spots and read more here: lnkd.in/gXe5UwKW
Emily Passer retweeted
NOOM LAUNCHES FREE VERSION OF ITS GLP-1 COMPANION
- Available at no cost to anyone taking a GLP-1, regardless of provider (e.g., $HIMS and Ro)
- Preliminary Noom data show that Noom members had roughly 3x stronger weight maintenance after stopping GLP-1s vs control group
Noom CEO @geoffcook is heading to the @ftlive x @endpts US Pharma & Biotech Summit on May 14, speaking on a panel tackling longevity medicine's biggest questions: what's driving innovation, where investment is going, and whether it's reaching the people who need it most.
Learn more: bit.ly/42Jw94A #FTPharma
Honored to be named to @TIME's inaugural TIME100 Companies: Industry Leaders list 🙌
The future of health isn't a drug or an app — it's what happens when lasting behavior change meets cutting-edge clinical care.
That's what we're building. bit.ly/420Ed0F
Tomorrow, Noom HQ in Princeton hosts our inaugural Noom Talks event, starting with Pulitzer Prize-winning journalist @cduhigg. We're diving into GLP-1s and the powerful window they open for habit formation and lasting change. Stay tuned for the recap. 🎤
🎉 Exciting news! Our Mindful Art Break feature has been nominated for @TheWebbyAwards in the Apps, Software & Immersive - Health, Wellness & Fitness category - built on the belief that a moment of awe can be a moment of healing.
Voting is open now through Thursday, April 16 at 11:59pm PDT - cast your vote here: bit.ly/3NAwHpN
Emily Passer retweeted
$HIMS $LLY $NVO
🚨 BREAKING: Noom is acquiring a 503A pharmacy to prepare for the peptide boom
We sat down with @GeoffCook (Noom CEO) to discuss why vertical integration is so important, how large the peptide market is going to be, and the evolving dynamics between telehealth platforms and big pharma
A great episode with one of the best CEOs in the game - thanks again, Geoff!
00:00 - Why pharma needs DTC platforms
03:03 - Noom's 90% revenue growth
05:01 - Why Noom bought Tailor Made Compounding
07:29 - The case for vertical integration
08:56 - Compounded GLP-1s aren't going anywhere
16:48 - The Hims-Novo deal
19:08 - Noom's pitch to next-gen pharma
24:24 - Peptide market sizing
25:33 - Why GLP-1 users will buy peptides first
27:22 - Ten million potential peptide patients 👀
30:09 - When will legalization happen?
31:09 - Tracking the FDA green list
34:26 - Who wins when peptides go legal?
37:58 - Why Noom won't rush peptide launch
39:33 - Geoff's BPC-157 ski injury recovery
46:42 - Expanding at-home labs past 30 biomarkers
52:47 - Noom IPO coming?!
Not financial, legal, or medical advice
Emily Passer retweeted
🚨 Excited to announce that Noom CEO @geoffcook will be returning to the $HIMS House podcast next week
💡 11 out of 12 people stop taking GLP-1s within a few years. GLP-1 therapy opens the door to change, but it doesn’t replace the need for sustained behavioral support.
That was the message from Noom CEO @geoffcook at the Stanford Consumer Health Summit.
Read the full story via @athletechnews 🔗 bit.ly/3PfiRt4
.@noom's CEO @geoffcook on what's next for GLP-1s: "We will see GLP-1s disrupt the supplement industry as they become the entry point for prescription-grade wellness."
Good expert roundup on where the category goes from here. 👇
Where does the GLP-1 story go from here? 👀
In a new expert roundup on what's next for GLP-1s, industry leaders weigh in - including Noom CEO @geoffcook, who shares how this drug class may help shape the future of proactive care.
Read more: bit.ly/4d1dgAw
1
115
We're honored to debut on @Newsweek's Most Trusted Brands 2026 list ✨
The article highlights how Noom continues to evolve - from habit science and GLP-1 support to biomarker testing and ongoing research - all in service of empowering everyone, everywhere to live better, longer every day.
Read the article featuring @geoffcook: bit.ly/3M9Wkge
New from @noom! Most logged foods by state: How Americans really eat... Quick questions... Missouri? Crab Rangoon? Really? Also, people of Arkansas who inputted just plain black coffee... are you okay?
noom.com/blog/nutrition/most…
1
74
Noom launches a GLP-1-based, long-term, preventive health care program usatoday.com/story/shopping/…
Some *personal news* (a 🧵 🪡 )… After more than 3.5 years, I’m moving on from Pagaya, where I was incredibly grateful to have worked with some wicked smart folks, share a powerful growth story and the company's important mission of expanding financial opportunity. 1/4
1
2
164
I’m energized by the opportunity to help shape and share their story at such an important moment in our health culture. You can check out some more here: noom.com/blog/ 4/4 :fin:
2
68












